Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of trontinemab for prevention or delay of symptomatic Alzheimer's disease in cognitively unimpaired at-risk individuals
2025-524314-29-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab with Placebo / matching trontinemab (2 arms). Primary endpoint: Time to progression. Planned start Sep 2026; status: authorised.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-524314-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524314-29-00.